Jasper Therapeutics (JSPR) Liabilities and Shareholders Equity (2019 - 2025)

Jasper Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $35.8 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 55.22% year-over-year to $35.8 million; the TTM figure through Dec 2025 stood at $197.3 million (down 52.93% YoY), while the FY2025 annual figure was $35.8 million, down 55.22% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $35.8 million, down from $57.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $138.8 million in Q1 2023, with the low at $35.8 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $94.3 million (2021), against an average of $87.3 million.
• The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity surged 300.97% in 2021, then slumped 59.21% in 2025.
• Jasper Therapeutics' Liabilities and Shareholders Equity stood at $93.7 million in 2021, then tumbled by 48.36% to $48.4 million in 2022, then soared by 96.22% to $94.9 million in 2023, then dropped by 15.8% to $79.9 million in 2024, then slumped by 55.22% to $35.8 million in 2025.
• Business Quant data shows JSPR's Liabilities and Shareholders Equity at $35.8 million in Q4 2025, $57.5 million in Q3 2025, and $46.5 million in Q2 2025.